Paul Hastings Advises BioMarin in $324,875,000 Public Offering of Senior Subordinated Convertible Notes
New York, NY (April 30, 2007) - Paul, Hastings, Janofsky & Walker LLP, a leading international law firm, announced today that it advised BioMarin in its closing of a $324,875,000 public offering of its 1.875 percent senior subordinated convertible notes due April 23, 2017. The sale included nearly $42.4 million of notes purchased by the underwriter through to its overallotment option.
The Paul Hastings team was represented by partners Thomas Pollock, Siobhan Burke and Michael Zuppone.
About BioMarin: BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease.
Paul Hastings Janofsky & Walker LLP, founded in 1951, is a leading international law firm with over 1,200 attorneys in 18 offices. The firm serves a diverse client base including including many of the leading global financial institutions and Fortune 500 companies and offers deep capabilities in Banking and Finance, Capital Markets, Corporate/M+A, Litigation and Dispute Resolution, Intellectual Property, Project Finance, Investment Management, Real Estate, Labor and Employment and Tax Advisory Services. For additional information, please visit our website at www.paulhastings.com.